Legicare Tablet contains Mifepristone 25 mg, a synthetic steroid compound primarily used for medical termination of intrauterine pregnancy. Mifepristone acts as a progesterone receptor antagonist, inhibiting the action of progesterone, a hormone essential for maintaining pregnancy. By blocking progesterone receptors, Legicare Tablet induces decidual breakdown and detachment of the blastocyst, leading to termination of early pregnancy. It is indicated for use within the first 63 days of gestation and is often administered in combination with prostaglandins to ensure complete abortion. In addition to its abortifacient properties, Mifepristone has applications in managing Cushing’s syndrome and as an emergency contraceptive in some protocols. The tablet should be used under strict medical supervision with appropriate counseling regarding its use, potential side effects, and contraindications. Common adverse effects include abdominal pain, uterine cramping, vaginal bleeding, nausea, vomiting, and fatigue. Contraindications include chronic adrenal failure, ectopic pregnancy, hemorrhagic disorders, and known hypersensitivity to the drug. Proper patient selection, adherence to dosing guidelines, and follow-up are essential to ensure safety and efficacy. Legicare Tablet should be stored in a cool, dry place away from direct sunlight and out of reach of children.